Related Experiment Video
Updated: Jul 4, 2026
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
Cytotoxic Effect of Thiabendazole on Hn5 Head and Neck Squamous Cell Carcinoma Cell Line
Amir Jalal Abassi1, Abdolreza Mohamadnia2, Seyed Alireza Parhiz1
1Craniomaxillofacial Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Statement Of The Problem:
Evidence shows thiabendazole has the potential to inhibit angiogenesis in melanoma and fibrosarcoma; however, its effect on oral squamous cell carcinoma has not been previously studied.
Purpose:
This study sought to assess the cytotoxic effects of thiabendazole on HN5 head and neck squamous carcinoma cell line.
Materials And Method:
HN5 cell lines were exposed to different concentrations of thiabendazole (prepared from 99% pure powder) for 24, 48 and 72 hours. Cell viability was assessed by the methyl thiazol tetrazolium assay, and IC50 of thiabendazole was calculated. Cells were also exposed to different concentrations of thiabendazole for 48 hours to determine its effect on expression and transcription of vascular endothelial growth factor gene. Expression of vascular endothelial growth factor mRNA was assessed by real-time polymerase chain reaction. The vascular endothelial growth factor release was assessed by the enzyme-linked immunosorbent assay test.
Results:
In all concentrations of thiabendazole except for 200 and 550μM, cell viability was significantly different at different time points (p< 0.05). At 48 and 72 hours, cell viability at all concentrations of thiabendazole (100-650μM) significantly decreased compared to the control group (zero concentration). In addition, cell viability significantly decreased with an increase in thiabendazole concentration. At 48 hours, expression of vascular endothelial growth factor mRNA was significantly lower in presence of 500μM thiabendazole compared to the control group (p< 0.001) and release of vascular endothelial growth factor was inhibited in a dose-dependent manner.
Conclusion:
Thiabendazole inhibited the proliferation of HN5 cells in a dose-dependent and time-dependent manner. It also inhibited the expression of vascular endothelial growth factor gene.
Insights
Thiabendazole significantly reduced oral squamous cell carcinoma cell viability and inhibited vascular endothelial growth factor gene expression. This study demonstrates thiabendazole
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Thiabendazole shows anti-angiogenic potential in melanoma and fibrosarcoma.
- Its effects on oral squamous cell carcinoma (OSCC) remain uninvestigated.
Purpose of the Study:
- To evaluate the cytotoxic impact of thiabendazole on the HN5 head and neck squamous carcinoma cell line.
- To assess thiabendazole's effect on vascular endothelial growth factor (VEGF) in OSCC.
Main Methods:
- HN5 cells were treated with varying thiabendazole concentrations for 24, 48, and 72 hours.
- Cell viability was measured using the MTT assay to determine IC50 values.
- VEGF gene expression and release were analyzed via real-time PCR and ELISA, respectively.
Main Results:
- Thiabendazole demonstrated a dose- and time-dependent decrease in HN5 cell viability (p < 0.05).
- Significant reduction in cell viability was observed at concentrations from 100-650μM.
- Thiabendazole (500μM) significantly suppressed VEGF mRNA expression (p < 0.001) and inhibited VEGF release.
Conclusions:
- Thiabendazole effectively inhibits proliferation of HN5 oral squamous cell carcinoma cells.
- The drug also suppresses vascular endothelial growth factor gene expression.
- Findings suggest thiabendazole's potential as an anti-cancer agent for OSCC.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
